Agile Therapeutics,Inc. (NASDAQ:AGRX) Files An 8-K Other Events

ME Staff 8-k
-
0

Agile Therapeutics,Inc. (NASDAQ:AGRX) Files An 8-K Other Events
Item 8.01.Other Events.

On October16, 2017, Agile Therapeutics,Inc. (“Agile”) a women’s healthcare company, announced the presentation of additional results from the Phase 3 SECURE trial of its investigational low-dose combination hormonal contraceptive patch, Twirla® (AG200-15). Anita Nelson, MD, Professor and Chair of Obstetrics and Gynecology at the College of Osteopathic Medicine of the Pacific, presented new data on the Twirla bleeding profile during a poster presentation at the 2017 North American Forum on Family Planning (NAFFP), “The Forum” in Atlanta, GA.

Copies of Agile’s press release and poster presentation are attached hereto as Exhibit99.1 and 99.2, respectively, and are hereby incorporated by reference herein.

Item 8.01. Financial Statements and Exhibits.

(d) Exhibits.


AGILE THERAPEUTICS INC Exhibit
EX-99.1 2 a17-23930_2ex99d1.htm EX-99.1 Exhibit 99.1   Agile Therapeutics Presents Additional Twirla® Phase 3 SECURE Study Results at NAFFP 2017   Detailed Bleeding Profile Data Provide Helpful Information for Patient Counseling   PRINCETON,…
To view the full exhibit click here

About Agile Therapeutics,Inc. (NASDAQ:AGRX)

Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.